Scarica l'app Stockscreener
1.88
3.09%
-0.06
Dopo l'orario di chiusura:
1.93
0.05
+2.66%
Precedente Chiudi:
$1.94
Aprire:
$1.94
Volume 24 ore:
40,602
Relative Volume:
0.57
Capitalizzazione di mercato:
$63.91M
Reddito:
-
Utile/perdita netta:
$-28.32M
Rapporto P/E:
-0.1773
EPS:
-10.6039
Flusso di cassa netto:
$-15.52M
1 W Prestazione:
-20.34%
1M Prestazione:
+2.73%
6M Prestazione:
-39.35%
1 anno Prestazione:
-61.32%
Intervallo 1D:
$1.83
$1.95
Intervallo di 1 settimana:
$1.83
$2.38
Portata 52W:
$1.28
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Nome
Dogwood Therapeutics Inc
Settore
Industria
Telefono
(866) 620-8655
Indirizzo
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
1.88 | 65.95M | 0 | -28.32M | -15.52M | -10.60 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dogwood Therapeutics Inc Borsa (DWTX) Ultime notizie
Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Price, News & Analysis - Kalkine
H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com Australia
Dogwood Therapeutics advances Halneuron for che... - pluang.com
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment - TradingView
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Dogwood (DWTX) Earnings Reading: The Available Earnings Metric Delivers a Beat in the Current Update; After Earnings: Shares Finish 6.87% Up in the Latest ReadingHigh Estimate Range - vinanet.vn
Dogwood (DWTX) Update: Records a 6.87% Increase to $2.49 at the Close; Boundary Watch: the Supplied Trading Band Runs From $2.37 to $2.61 in the Latest SessionImpulse Wave - vinanet.vn
Armistice Capital Expands Dogwood Therapeutics Stake Amid Biotec - GuruFocus
Dogwood (DWTX) Quarterly Results: EPS Lands Above Forecast; Market Move: Shares Move 7.79% Lower on the DayTax Rate Impact - vinanet.vn
Dogwood (DWTX) Earnings Reading: Profit Per Share Clears Its Benchmark in the Current Update; Latest Reaction - vinanet.vn
Research Analysts Offer Predictions for DWTX Q3 Earnings - MarketBeat
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - The Manila Times
Halneuron Has Been Tested on More Than 800 Patients—What’s Next? - Stock Titan
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for - GlobeNewswire
What is HC Wainwright's Forecast for DWTX FY2029 Earnings? - MarketBeat
Dogwood Therapeutics, Inc. 2026: Revenue ($14.06M), EPS ($0.34) — 10-Q Summary - TradingView
Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook - Stock Titan
Armistice Capital (DWTX) discloses 9.99% Dogwood Therapeutics ownership in 13G/A - Stock Titan
Maxim Group Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat
Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Dogwood Therapeutics Reports $11.5 Million Second-Quarter Net Loss - Quiver Quantitative
Dogwood Therapeutics reports Q2 2026 net loss of $11.5M, IPR&D charge of $9.19M; $9.6M cash - TradingView
DWTX: Halneuron Phase 2b trial nears completion as Q2 net loss widens on higher R&D and impairment - TradingView
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Dogwood Therapeutics (DWTX) Rises 2.78% as Buyers Defend Key $1.76 SupportMAMA Signal - vinanet.vn
Dogwood Therapeutics Inc (DWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dogwood Therapeutics Inc (DWTX) Stock News Today - TradingKey
Dogwood Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Wednesday - marketbeat.com
Dogwood Therapeutics (DWTX) Holds Steady at $1.79: Key Levels to Watch as Biotech Stock ConsolidatesDealer Gamma - vinanet.vn
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3%What's Next? - MarketBeat
Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline - Bitget
Dogwood Therapeutics Inc (DWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise - vinanet.vn
Dogwood Therapeutics, Inc. Revenue Breakdown – NASDAQ:DWTX - TradingView
Dogwood Therapeutics Inc (DWTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dogwood Therapeutics Inc (DWTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DWTX|Dogwood Therapeutics Inc|Price:1.530|Chg%:+0.030 - TradingKey
Dogwood Therapeutics Market Sentiment - Benzinga España
Dogwood Therapeutics Inc (DWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DWTX Q1 2026 Earnings: EPS Beats by 42.7% as Pre-Revenue Biotech Charts Path ForwardDividend Growth Analysis - vinanet.vn
Dogwood Therapeutics Inc (DWTX) Balance Sheet - TradingKey
Dogwood Therapeutics Inc (DWTX) Income Statement - TradingKey
Dogwood Therapeutics Inc (DWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower Net Loss Exceeds Consensus Expectations Amid Clinical DevelopmentLong-Term Guidance - dars.gov.et
TradingKey - TradingKey
DWTX|Dogwood Therapeutics Inc|Price:2.360|Chg%:-0.120 - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline Despite No RevenueRevenue Report - dars.gov.et
Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial - marketscreener.com
Dogwood Therapeutics Inc Azioni (DWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):